181 related articles for article (PubMed ID: 31597839)
1. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract][Full Text] [Related]
2. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
3. [8p11 myeloproliferative syndrome].
Li F; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1073-7. PubMed ID: 23998615
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
5. [Clinical pathological features of the 8p11 myeloproliferative syndrome].
Yan Z; Yang B; Wang QS; Wang LL; Han XP; Ren F; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1321-6. PubMed ID: 21129285
[TBL] [Abstract][Full Text] [Related]
6. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.
Chen M; Wang K; Cai X; Zhang X; Chao H; Chen S; Shen H; Wang Q; Zhang R
Hematology; 2021 Dec; 26(1):153-159. PubMed ID: 33491601
[No Abstract] [Full Text] [Related]
7. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and
Wehrli M; Oppliger Leibundgut E; Gattiker HH; Manz MG; Müller AM; Goede JS
Oncologist; 2017 Apr; 22(4):480-483. PubMed ID: 28242791
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review.
Konishi Y; Kondo T; Nakao K; Asagoe K; Otsuka Y; Nishikori M; Hishizawa M; Yamashita K; Takaori-Kondo A
Bone Marrow Transplant; 2019 Feb; 54(2):326-329. PubMed ID: 30087462
[No Abstract] [Full Text] [Related]
9. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.
Patnaik MM; Gangat N; Knudson RA; Keefe JG; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
Am J Hematol; 2010 Apr; 85(4):238-42. PubMed ID: 20143402
[TBL] [Abstract][Full Text] [Related]
10. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.
Macdonald D; Reiter A; Cross NC
Acta Haematol; 2002; 107(2):101-7. PubMed ID: 11919391
[TBL] [Abstract][Full Text] [Related]
11. 8p11 myeloproliferative syndrome: a review.
Jackson CC; Medeiros LJ; Miranda RN
Hum Pathol; 2010 Apr; 41(4):461-76. PubMed ID: 20226962
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant.
Zhang WW; Habeebu S; Sheehan AM; Naeem R; Hernandez VS; Dreyer ZE; López-Terrada D
J Pediatr Hematol Oncol; 2009 Nov; 31(11):879-83. PubMed ID: 19829149
[TBL] [Abstract][Full Text] [Related]
13. [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].
Liu YT; Zhao JW; Feng J; Li QH; Chen YM; Qiu LG; Xiao ZJ; Li Y; Gong BF; Gong XY; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):848-852. PubMed ID: 31775485
[No Abstract] [Full Text] [Related]
14. 8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls.
Antic DA; Vukovic VM; Milosevic Feenstra JD; Kralovics R; Bogdanovic AD; Dencic Fekete MS; Mihaljevic BS
J BUON; 2016; 21(3):745-9. PubMed ID: 27569099
[TBL] [Abstract][Full Text] [Related]
15. Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Yamamoto S; Otsu M; Matsuzaka E; Konishi C; Takagi H; Hanada S; Mochizuki S; Nakauchi H; Imai K; Tsuji K; Ebihara Y
PLoS One; 2015; 10(3):e0120841. PubMed ID: 25803811
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
[TBL] [Abstract][Full Text] [Related]
17. The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy.
Li T; Zhang G; Zhang X; Lin H; Liu Q
Front Oncol; 2022; 12():1015792. PubMed ID: 36408177
[TBL] [Abstract][Full Text] [Related]
18. Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child.
Chen X; Zhang Y; Li Y; Lei P; Zhai Y; Liu L
J Pediatr Hematol Oncol; 2010 Aug; 32(6):501-3. PubMed ID: 20562652
[TBL] [Abstract][Full Text] [Related]
19. 8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature.
Kim WS; Park SG; Park G; Jang SJ; Moon DS; Kang SH
Acta Haematol; 2015; 133(1):101-5. PubMed ID: 25227135
[TBL] [Abstract][Full Text] [Related]
20. [Characteristic of 8p11 Myeloproliferative Syndrome with Rare Phenotype].
Xue S; Xu HX; Zhang YP; Liu FH; Lu YY; Li F; Wang YP; Wang CC; Jia XP; Wang JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):181-187. PubMed ID: 33554816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
